MSLN and sarcoma: Knockout of endogenous TCR components in autologous ACT cells is therefore adopted in two clinical trials with either tTCR-T cells redirected against NY-ESO-1 (in MM, melanoma, or subtypes of sarcoma)133 or CAR-T cells redirected against mesothelin (in any mesothelin-positive solid tumor).134